Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2220)	10/13/2008 11:27:51 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MRNA is up 20% in spite of the poor results in its first 2Qs.<g> Volume remains low & there have benn no news since it announced last week that it had advanced its RNAi pipeline with the selection of MDR-04227 as its Lead Candidate in its hypercholesterolemia program targeting ApoB. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2220)	11/30/2010 9:47:30 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

AMRN wants to continue its UT in spite of the GM doldrums.<g> It seems that the stock isn't yet interested in closing yesterday's UG.<g> bigcharts.marketwatch.com Yesterday's UG was triggered by AMRN reporting positive, statistically significant results from the PIII MARINE study of AMR101. The MARINE study was for evaluation of AMR101 as treatment for very high triglycerides, and it met its primary efficacy endpoints with an also positive safety profile.<g> AMRN expects that AMR101 will be the best-in-class product for hypertriglyceridemia and that the MARINE study results may support additional patentable claims that could further protect the AMRN's rights to this drug through 2030. Some important points taken from the MARINE PIII were that in the subgroup of patients on background statin therapy,AMR101 had much greater median reductions in triglycerides than those not on statin therapy.(Some synergistic effect. <g>) Also, AMR101 didn't cause an increase in LDL-C compared to placebo.<g> This is the first and only triglyceride-lowering therapy studied in this population with very high triglyceride levels to show a lack of elevation in LDL-C. The stock is trading above yesterday's H, and the ACTAY, which remains at $5.23 <g> It is up 4.44% on volume of >371Ks stockcharts.com In spite of the general market and yesterday's UG, that hasn't been closed, it seems that the stock has plenty of room to run.<G> bigcharts.marketwatch.com Bernard